BioPharmX Corporation stock performance trend indicates that the stock price has rallied 34.48% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -5.41% . Looking at the past 52 week period, the stock price is down -61.11% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of BioPharmX Corporation has a negative value of -38.95 compared to overall market performance.BioPharmX Corporation is having a Relative Strength Index of 62.46 which indicates the stock is not yet over sold or over bought based on the technical indicators.
BioPharmX Corporation (NYSEMKT:BPMX) has climbed 19.32% in the past week and advanced 16.67% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 19.04% and the outperformance has advanced to 15.34% for the last 4 weeks period.
For the current week, the company shares have a recommendation consensus of Buy. BioPharmX Corporation (NYSEMKT:BPMX) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.0279 points or 5.05% at $0.525 with 1,431,019 shares getting traded. Post opening the session at $0.57, the shares hit an intraday low of $0.5121 and an intraday high of $0.58 and the price was in this range throughout the day. The company has a market cap of $36 million and the number of outstanding shares has been calculated to be 67,719,577 shares. The 52-week high of BioPharmX Corporation (NYSEMKT:BPMX) is $1.5 and the 52-week low is $0.1883.
Company has reported several Insider transactions to the SEC, on Nov 29, 2016, Stephen Morlock (director) purchased 428,571 shares at 0.35 per share price.On Aug 16, 2016, Resources Inc Franklin (10% owner) purchased 484,615 shares at 0.65 per share price.
BioPharmX Corporation is a specialty pharmaceutical company. The company focuses on the development of novel drug delivery products for womens health, dermatology and otolaryngology markets. The Companys product pipeline includes products in categories consists of prescription products, over-the-counter products and dietary supplements. Prescription products in development include molecular iodine pill for the treatment of breast pain associated with fibrocystic breast disease. OTC product pipeline includes a series of medicated bandages, nasal sprays and other products. Supplement product pipeline includes BioPharmXs breast health pill. Its product candidates include BPX03 a molecular iodine tablet for the treatment of benign breast pain associated with FBC and cyclic mastalgia and BPX01 a non-lipophilic topical antibiotic for the treatment of acne. BioPharmX Corporation is headquartered in Menlo Park, California.